Literature DB >> 15769985

Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics.

Michael B Chen1, Andrew J McAinch, S Lance Macaulay, Laura A Castelli, Paul E O'brien, John B Dixon, David Cameron-Smith, Bruce E Kemp, Gregory R Steinberg.   

Abstract

Adiponectin is an adipocyte-derived hormone associated with antidiabetic actions. In rodent skeletal muscle, globular adiponectin (gAD) activates AMP-kinase (AMPK) and stimulates fatty acid oxidation effects mediated through the adiponectin receptors, AdipoR1 and AdipoR2. In the present study, we examined the mRNA expression of adiponectin receptors and the effects of gAD on AMPK activity and fatty acid oxidation in skeletal muscle myotubes from lean, obese, and obese type 2 diabetic subjects. Myotubes from all groups expressed approximately 4.5-fold more AdipoR1 mRNA than AdipoR2, and obese subjects tended to have higher AdipoR1 expression (P = 0.052). In lean myotubes, gAD activates AMPKalpha1 and -alpha2 by increasing Thr172 phosphorylation, an effect associated with increased acetyl-coenzyme A carboxylase (ACCbeta) Ser221 phosphorylation and enhanced rates of fatty acid oxidation, effects similar to those observed after pharmacological AMPK activation by 5-aminoimidazole-4-carboxamide riboside. In obese myotubes, the activation of AMPK signaling by gAD at low concentrations (0.1 mug/ml) was blunted, but higher concentrations (0.5 mug/ml) stimulated AMPKalpha1 and -alpha2 activities, AMPK and ACCbeta phosphorylation, and fatty acid oxidation. In obese type 2 diabetic myotubes, high concentrations of gAD stimulated AMPKalpha1 activity and AMPK phosphorylation; however, ACCbeta phosphorylation and fatty acid oxidation were unaffected. Reduced activation of AMPK signaling and fatty acid oxidation in obese and obese diabetic myotubes was not associated with reduced protein expression of AMPKalpha and ACCbeta or the expression and activity of the upstream AMPK kinase, LKB1. These data suggest that reduced activation of AMPK by gAD in obese and obese type 2 diabetic subjects is not caused by reduced adiponectin receptor expression but that aspects downstream of the receptor may inhibit AMPK signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769985     DOI: 10.1210/jc.2004-1980

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  57 in total

1.  Reduced cardioprotective action of adiponectin in high-fat diet-induced type II diabetic mice and its underlying mechanisms.

Authors:  Wei Yi; Yang Sun; Erhe Gao; Xufeng Wei; Wayne Bond Lau; Qijun Zheng; Yajing Wang; Yuexing Yuan; Xiaoliang Wang; Ling Tao; Rong Li; Walter Koch; Xin-Liang Ma
Journal:  Antioxid Redox Signal       Date:  2011-04-11       Impact factor: 8.401

2.  Physiological glucose is critical for optimized neuronal viability and AMPK responsiveness in vitro.

Authors:  Amy M Kleman; Jason Y Yuan; Susan Aja; Gabriele V Ronnett; Leslie E Landree
Journal:  J Neurosci Methods       Date:  2007-09-07       Impact factor: 2.390

3.  Role of adiponectin in human skeletal muscle bioenergetics.

Authors:  Anthony E Civitarese; Barbara Ukropcova; Stacy Carling; Matthew Hulver; Ralph A DeFronzo; Lawrence Mandarino; Eric Ravussin; Steve R Smith
Journal:  Cell Metab       Date:  2006-07       Impact factor: 27.287

4.  Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response.

Authors:  Masayuki Shimano; Noriyuki Ouchi; Rei Shibata; Koji Ohashi; David R Pimentel; Toyoaki Murohara; Kenneth Walsh
Journal:  J Mol Cell Cardiol       Date:  2010-03-04       Impact factor: 5.000

5.  Sex differences in the regulation of porcine coronary artery tone by perivascular adipose tissue: a role of adiponectin?

Authors:  Abdulla A Ahmad; Michael D Randall; Richard E Roberts
Journal:  Br J Pharmacol       Date:  2017-07-12       Impact factor: 8.739

Review 6.  Roles of AMP-activated protein kinase in Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Keshen Li; Sohel H Quazi; Bin Zhao
Journal:  Neuromolecular Med       Date:  2012-02-26       Impact factor: 3.843

7.  Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signalling.

Authors:  R M Holmes; Z Yi; E De Filippis; R Berria; S Shahani; P Sathyanarayana; V Sherman; K Fujiwara; C Meyer; C Christ-Roberts; H Hwang; J Finlayson; L Q Dong; L J Mandarino; M Bajaj
Journal:  Diabetologia       Date:  2011-05-12       Impact factor: 10.122

8.  Increased pyruvate dehydrogenase kinase expression in cultured myotubes from obese and diabetic individuals.

Authors:  A J McAinch; L M Cornall; R Watts; D H Hryciw; P E O'Brien; D Cameron-Smith
Journal:  Eur J Nutr       Date:  2014-10-14       Impact factor: 5.614

Review 9.  Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure.

Authors:  An M Van Berendoncks; Anne Garnier; Renée Ventura-Clapier; Viviane M Conraads
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

10.  What can adiponectin say about left ventricular function?

Authors:  Flora Sam; Kenneth Walsh
Journal:  Heart       Date:  2009-11-23       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.